Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Anesth Analg. 2020 Aug;131(2):555–563. doi: 10.1213/ANE.0000000000004553

Table 2.

Clinical outcomes of patients presenting moderate/severe postoperative hypoxemic (POH) events. Values are shown as mean (SD) or N (% of group) unless otherwise indicated.

Total No POH POH P value
(N=43,011) (N=32,284) (N=10,727)
Postoperative In-hospital Course
Patients With At Least One Hypoxemic Event (SpO2 ≤85%, any duration):
 PACU (not considered POH) 1,585 (3.7%) 1,018 (3.2%) 567 (5.3%) <0.001
 POD 1 7,179 (16.7%) 0 (0.0%) 7,179 (66.9%) <0.001
 POD 2 5,340 (12.4%) 0 (0.0%) 5,340 (49.8%) <0.001
 POD 3 3,455 (8.0%) 0 (0.0%) 3,455 (32.2%) <0.001
 Any POH event on POD 1, 2, or 3 10,727 (24.9%) 0 (0.0%) 10,727 (100.0%)
% of Hypoxemic Events (POH%) *
 POD 1 2.4 (6.7) 0 (0.0) 9.5 (10.6) <0.001
 POD 2 1.9 (6.3) 0 (0.0) 7.5 (10.8) <0.001
 POD 3 1.2 (5.3) 0 (0.0) 4.9 (9.8) <0.001
Postoperative O2 Therapy Duration, days 3.7 (5.4) 3.1 (5.3) 5.3 (5.5) <0.001
Postoperative NIV (CPAP, BiPAP, APAP) 5,905 (13.7%) 3,783 (11.7%) 2,122 (19.8%) <0.001
Postoperative Reintubation 1,535 (3.6%) 1,025 (3.2%) 510 (4.8%) <0.001
ICU Admission:
 Planned (direct transfer after surgery) 4,447 (10.3%) 2,849 (8.8%) 1,598 (14.9%) <0.001
 Unplanned (>12h after PACU discharge) 926 (2.2%) 500 (1.5%) 426 (4.0%) <0.001
Hospital Length of Stay, days 4.9 (5.8) 4.5 (5.7) 6.1 (5.9) <0.001
Death within 1 year from DOS 1,426 (3.3%) 958 (3.0%) 468 (4.4%) <0.001
*

The frequency of POH events is expressed as percentage of hypoxemia events out of the total SpO2 measurements per day for POD 1–3.

(APAP=Auto-titrating Positive Airway Pressure; BiPAP= Bi-level Positive Airway Pressure; CPAP=Continuous Positive Airway Pressure; DOS=Date of Service; ICU=Intensive Care Unit; NIV=Non-Invasive Ventilation, including CPAP, APAP or BiPAP; PACU=Post-Anesthesia Care Unit; POD=Postoperative Day; POH= Postoperative Hypoxemia, SpO2=Peripheral Saturation of Oxyhemoglobin by pulse oximetry)